University of Wisconsin–Madison

Meet the 2019 August LOL Speakers

The Land O’ Lakes Pharmaceutical Analysis Conference provides a forum to share new scientific and regulatory developments in the areas related to or with direct application for pharmaceutical analysis, product development, product quality and the analytical method lifecycle applications.

The Land O’ Lakes Pharmaceutical Analysis Conference is designed for interaction. Our speakers are happy to converse with you and answer your questions during networking breaks. 

This year we will host the following pre-conference short courses on key pharmaceutical analysis topics:

You will find our complete lineup of topics and speakers at our website

Here is a sample of what you can expect as we celebrate 59 years of the Pharmaceutical Analysis Conference.  

Learn More and Register

My research group focuses on the design, synthesis/fabrication, and characterization of novel materials and devices. Many of our group’s on-going projects are multidisciplinary, bridging engineering with materials science, chemistry, and the life sciences. Our ultimate goal is to create nanomedicines and nanomaterials for human health and sustainable energy applications. I look forward to presenting at the Pharmaceutical Analysis conference, and interacting with you all.

Shaoqin “Sarah” Gong, PhD
Vilas Distinguished Achievement Professor
Wisconsin Institute for Discovery, University of Wisconsin-Madison

Hi, I am Holly Bridges. In my role I am responsible to manage and improve our electronic laboratory systems and documentation processes. I will be talking about Improving Laboratory Documentation Systems for Accuracy and Efficiency at the August 2019 Land O Lakes Pharmaceutical Analysis Conference on Wednesday, August 14, 2019.  I am really excited to be speaking to other scientists about this topic because the knowledge that flows through a thoughtfully-designed laboratory documentation system can enable scientific decision-making and empower scientists. I look forward to seeing you there.

Holly Bridges
R&D Operations Supervisor
Perrigo Company plc

I am Kristy Moeller, an Associate Research Scientist in the Physical and Chemical Characterization department at PPD Laboratories, where my team performs various quality tests on pharmaceutical compounds for our clients. I will be talking about “Foreign Particulate Matter Analysis of Biologics: Review, Challenges, and Case Studies” at the August 2019 Land O’ Lakes Pharmaceutical Analysis Conference on August 13th. This topic is important because biologic products are a rapidly growing segment of the pharmaceutical landscape, and the challenges these types of products pose for quality testing must be understood in order to quickly and safely develop these types of therapies for patients. I look forward to seeing you there.

Kristy Moeller
Associate Research Scientist
Physical and Chemical Characterization, PPD Laboratories

I have been working in the area of protein and antibody characterization for the past 10 plus years. I have been at PPD for approximately 18 months working in the large molecule group, looking at both proteins and oligonucleotides. I am looking forward to presenting different methods for oligonucleotide sequence confirmation that are used at PPD along with some of the pros and cons. I look forward to talking with you in Madison.

Gordon Nicol, PhD
Principal Scientist

Hi, I am Derek Vrieze, Associate Director of Regulatory CMC at Vertex Pharmaceuticals. I will be talking about regulatory solutions for accelerated development at the “August 2019 Land O’ Lakes Pharmaceutical Analysis Conference” on August 13.  I am really excited to be presenting this topic. It is important because as more opportunities for accelerated review and approval have become available, development functions are feeling the pressure to keep pace. I look forward to seeing you there.

Derek Vrieze
Associate Director
Global Regulatory Affairs CMC, Vertex Pharmaceuticals

Hi, I am Ray Xie. I’m currently working in the Spectroscopy Center of Excellent (CoE), which focuses on using mass spectrometry and NMR spectroscopy to support drug development with regard to identification, quantification, and control of trace level potentially mutagenic impurities (PMIs), unknown impurities, elemental impurities and polymorphic impurities, in order to meet the current health authority requirements. On August 14, I will talk about New Technologies for Testing Trace Level Pharmaceutical Impurities: Processes, Procedures and Tactics. I look forward to seeing you there and having a great discussion with you.

Ruimin “Ray” Xie
Senior Scientist
Analytical Development, Celgene Corporation

Learn More and Register